Bo Cheng
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Bo Cheng has a total of 8 co-authors. Here are the top co-authors by number of shared publications:
- Abiola Abdulrahman Ayanlaja
Department of Neurology, Johns Hopkins University School of Medicine, 201 N Broadway, Baltimore, MD 21287, USA
2 shared publications - Caiyi Zhang
Department of child and adolescent psychology, The Affiliated Xuzhou Oriental Hospital of Xuzhou Medical University, Xuzhou, China
2 shared publications - Jing Zhu
Department of Psychiatry, The Affiliated Xuzhou Eastern Hospital of Xuzhou Medical University, Tongshan Road 379, Xuzhou 221000, China
2 shared publications - Wei Hu
Department of Psychiatry, The Affiliated Xuzhou Eastern Hospital of Xuzhou Medical University, Tongshan Road 379, Xuzhou 221000, China
2 shared publications - Yu Wang
Department of Geriatric Psychiatry, The Affiliated Brain Hospital of Nanjing Medical University, Guangzhou Road 264, Nanjing 220029, China
2 shared publications - Ziqiang Qiu
Department of Psychiatry, The Affiliated Xuzhou Eastern Hospital of Xuzhou Medical University, Tongshan Road 379, Xuzhou 221000, China
2 shared publications
Latest Publications
- Open Access
Correction: Cheng et al. Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways. Cells 2022, 11, 3232
The authors wish to make the following change to their paper
Open AccessCorrection: Cheng et al. Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways. Cells 2022, 11, 3232
The authors wish to make the following change to their paper
- Open Access
Glutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways
The glutathione S-transferase (GST) family of detoxification enzymes can regulate the malignant progression and drug resistance of various tumors. Hematopoietic prostaglandin D synthase (HPGDS, also referred to as GSTS1), GSTZ1, and GSTA1 are abnormally expressed in multiple cancers, but their roles in tumorigenesis and development remain unclear. In this study, we used bioinformatics tools to analyze the connections of HPGDS, GSTZ1, and GSTA1 to a variety of tumors in genetic databases. Then, we performed biochemical assays in GBM cell lines to investigate the involvement of HPGDS in proliferation and drug resistance. We found that HPGDS, GSTZ1, and GSTA1 are abnormally expressed in a variety of tumors and are associated with prognoses. The expression level of HPGDS was significantly positively correlated with the grade of glioma, and high levels of HPGDS predicted a poor prognosis. Inhibiting HPGDS significantly downregulated GBM proliferation and reduced resistance to temozolomide by disrupting the cellular redox balance and inhibiting the activation of JNK signaling. In conclusion, this study suggested that HPGDS, GSTZ1, and GSTA1 are related to the progression of multiple tumors, and HPGDS is expected to be a prognostic factor in GBM.
Open AccessGlutathione S-Transferases S1, Z1 and A1 Serve as Prognostic Factors in Glioblastoma and Promote Drug Resistance through Antioxidant Pathways
The glutathione S-transferase (GST) family of detoxification enzymes can regulate the malignant progression and drug resistance of various tumors. Hematopoietic prostaglandin D synthase (HPGDS, also referred to as GSTS1), GSTZ1, and GSTA1 are abnormally expressed in multiple cancers, but their roles in tumorigenesis and development remain unclear. In this study, we used bioinformatics tools to analyze the connections of HPGDS, GSTZ1, and GSTA1 to a variety of tumors in genetic databases. Then, we performed biochemical assays in GBM cell lines to investigate the involvement of HPGDS in proliferation and drug resistance. We found that HPGDS, GSTZ1, and GSTA1 are abnormally expressed in a variety of tumors and are associated with prognoses. The expression level of HPGDS was significantly positively correlated with the grade of glioma, and high levels of HPGDS predicted a poor prognosis. Inhibiting HPGDS significantly downregulated GBM proliferation and reduced resistance to temozolomide by disrupting the cellular redox balance and inhibiting the activation of JNK signaling. In conclusion, this study suggested that HPGDS, GSTZ1, and GSTA1 are related to the progression of multiple tumors, and HPGDS is expected to be a prognostic factor in GBM.